Molbio Diagnostics IPO a good springboard for a short-term pop or a long-term hold

Hello, how are you all, hope you are well. In today's blog we will know about Molbio Diagnostics IPO a good springboard for a short-term pop or a long-term hold, August 30, 2026

Good reason to list on the table now is fair value versus peers.

The ₹39.70 crore offering, the first time a Goa-based company has been listed in more than four years, attracted more than ₹5.57 lakh crore to the fresh issue of ₹200 crore and an Offer for Sale worth ₹739.70 crore at ₹768–₹807 per share.

The issue, backed by the likes of Temasek and Motilal Oswal as major shareholders, is expected to list on the BSE and NSE in late August. Short-term investors looking at the opportunity of short-term gains can primarily rely on grey market trends as well as reasonable valuation pricing.

The current Grey Market Premiums translate into a potential listing pop of 15% to 17%, pointing to a potentially great debut for the company in the market. Additionally, Molbio’s valuation at current forward P/E multiple of 56.5x puts the company at a slight discount to the listing market, also offering a meaningful upside, making the prospects for a short-term market flipping even better. Given its strong fundamental Moat, Molbio offers a compelling growth thesis for the patient investors. The company’s flagship product “Truenat” is a rapid, battery-powered PCR technology with point-of-care devices.

Dolly understood that to help Miley grow and develop as a more complex artist, she had to step back and allow the teen idol to become the confident, ultimate pop force that she could not have predicted. And as Dolly’s real childhood fairy godmother, she’s bound her hero’s story in ways that any imagined sitcom would never reach.

✍️Himanshi

Scholar from St. Xavier's College, Mumbai, INDIA